目的 探討痹祺膠囊聯(lián)合塞來昔布治療膝骨性關(guān)節(jié)炎的臨床療效。方法 選取2013年10月—2016年8月天津中醫(yī)藥大學(xué)第一附屬醫(yī)院收治的膝骨性關(guān)節(jié)炎患者85例，根據(jù)治療方式的不同將患者分為對照組（42例）和治療組（43例）。對照組患者口服塞來昔布膠囊，1粒/次，2次/d；治療組患者在對照組的基礎(chǔ)上口服痹祺膠囊，2粒/次，2次/d。兩組患者治療時間均為8周。評價治療后兩組患者臨床療效，同時比較治療前后兩組Lequesnse指數(shù)、WOMAC評分和血清炎癥指標(biāo)變化。結(jié)果 治療后，對照組的總有效率為73.81%，顯著低于治療組的90.70%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組患者Lequesnse指數(shù)和WOMAC評分均顯著降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）；且治療組患者Lequesnse指數(shù)和WOMAC評分下降更顯著，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組患者血清超敏C-反應(yīng)蛋白（hs-CRP）、白細(xì)胞介素-1（IL-1）、IL-6水平較治療前均明顯降低（P< 0.05）；且治療后治療組患者h(yuǎn)s-CRP、IL-1、IL-6水平顯著優(yōu)于對照組（P< 0.05）。結(jié)論 痹祺膠囊聯(lián)合塞來昔布治療膝骨性關(guān)節(jié)炎臨床療效較好，能夠顯著改善膝關(guān)節(jié)功能，并降低血清炎癥因子水平，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the clinical effect of Biqi Capsules combined with celecoxib in treatment of knee osteoarthritis. Methods Patients (85 cases) with knee osteoarthritis in the First Teaching Hospital of Tianjin University of TCM from October 2013 to August 2016 were divided into control (42 cases) and treatment (43 cases) groups based on different treatments. Patients in the control group were po administered with Celecoxib Capsules, 1 grain/time, twice daily. Patients in the treatment group were po administered with Biqi Capsules on the basis of the control group, 2 grains/time, twice daily. Patients in two groups were treated for 8 weeks. After treatment, clinical efficacy was evaluated, and Lequesnse index, WOMAC scores, and serum inflammatory markers in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 73.81%, which was significantly lower than 90.70% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the Lequesnse index and WOMAC scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). The Lequesnse index and WOMAC scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the hs-CPR, IL-1, and IL-6 levels in two groups were significantly decreased (P < 0.05). And these serum inflammatory markers levels in treatment group were significantly better than those in the control group (P < 0.05). Conclusion Biqi Capsules combined with celecoxib has excellent clinical effect in treatment of knee osteoarthritis, which can significantly improve the knee function and reduce the level of serum inflammatory factors, which has a certain clinical application value.